Royal Bank Of Canada Issues Positive Forecast for Pharvaris (NASDAQ:PHVS) Stock Price

Key Points

• Royal Bank of Canada raised Pharvaris’ price target to $62 from $52 and maintained an “outperform” rating, implying approximately 64.85% upside from the reported $37.61 share price.
• Analyst sentiment is broadly positive: 12 analysts rate the stock Buy, one rates it Hold and one rates it Sell, producing a “Moderate Buy” consensus and a $55.23 average price target.
• Pharvaris reported positive Phase 3 results for its oral HAE treatment and plans regulatory submissions beginning in the first half of 2027, though it remains a loss-making clinical-stage biotech and recently missed quarterly EPS expectations.

Pharvaris (NASDAQ:PHVS - Get Free Report) had its target price upped by equities researchers at Royal Bank Of Canada from $52.00 to $62.00 in a report issued on Wednesday, Benzinga reports. The brokerage currently has an "outperform" rating on the stock. Royal Bank Of Canada's target price indicates a potential upside of 64.85% from the company's current price.

Several other research firms have also weighed in on PHVS. Wedbush restated an "outperform" rating and set a $42.00 target price on shares of Pharvaris in a report on Tuesday. Citigroup reissued a "market outperform" rating on shares of Pharvaris in a report on Wednesday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Pharvaris in a research note on Friday, July 17th. UBS Group set a $79.00 price target on Pharvaris in a research note on Wednesday. Finally, Wells Fargo & Company reiterated an "overweight" rating and issued a $65.00 price objective on shares of Pharvaris in a research report on Wednesday. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Pharvaris presently has a consensus rating of "Moderate Buy" and a consensus price target of $55.23.

Pharvaris Stock Down 0.6%

PHVS stock opened at $37.61 on Wednesday. The company has a 50 day moving average of $34.86 and a two-hundred day moving average of $31.20. The company has a market cap of $2.46 billion, a price-to-earnings ratio of -12.37 and a beta of -2.33. Pharvaris has a 12-month low of $20.65 and a 12-month high of $43.25.

Pharvaris (NASDAQ:PHVS - Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). On average, research analysts anticipate that Pharvaris will post -3.15 EPS for the current year.

Insider Transactions at Pharvaris

In other Pharvaris news, insider Anne Lesage sold 30,703 shares of the company's stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total value of $1,089,649.47. Following the sale, the insider directly owned 93,969 shares in the company, valued at $3,334,959.81. This represents a 24.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Johannes Gerardus Chri Schikan sold 30,712 shares of the stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total value of $1,089,968.88. Following the transaction, the director owned 315,167 shares of the company's stock, valued at $11,185,276.83. This represents a 8.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 118,655 shares of company stock valued at $4,188,002. Corporate insiders own 11.84% of the company's stock.

Institutional Investors Weigh In On Pharvaris

Several institutional investors and hedge funds have recently made changes to their positions in PHVS. Quantbot Technologies LP acquired a new stake in shares of Pharvaris during the 2nd quarter worth about $41,000. JPMorgan Chase & Co. boosted its holdings in shares of Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company's stock worth $59,000 after acquiring an additional 783 shares in the last quarter. Barclays PLC acquired a new position in shares of Pharvaris in the 4th quarter worth approximately $77,000. CoreCap Advisors LLC bought a new stake in Pharvaris during the 2nd quarter worth approximately $93,000. Finally, Nano Cap New Millennium Growth Fund L P bought a new stake in Pharvaris during the 4th quarter worth approximately $139,000.

More Pharvaris News

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Phase 3 CHAPTER-3 trial met all key objectives: Pharvaris reported statistically significant and clinically meaningful results for the primary endpoint and every secondary efficacy endpoint. Deucrictibant XR reduced HAE attacks, supporting its potential as an oral prophylactic option. Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study
• Positive Sentiment: Regulatory submissions are planned: The company expects to use CHAPTER-3 data in marketing applications beginning in the first half of 2027, marking a significant step toward potential commercialization. Pharvaris' genetic disorder drug meets main goal in late-stage trial
• Positive Sentiment: Analyst support strengthened: Wedbush maintained an Outperform rating with a $42 target, while RBC raised its target to $62 from $52 and kept an Outperform rating. HC Wainwright also reaffirmed Buy with a $60 target. A separate analyst compilation reported a consensus target of $51.08. RBC Raises Price Target on Pharvaris
• Neutral Sentiment: Key risks remain: Pharvaris is still a clinical-stage, loss-making biotechnology company, and RBC continues to classify the shares as carrying speculative risk. Future performance will depend on regulatory review, additional data and successful commercialization.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.